MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, December 25, 2014

Biogen Straps Fitbits Onto MS Patients' Wrists

The company, which has five MS drugs on the market, gave out 250 Fitbit bands to MS patients in the U.S. last spring to track their level of activity and sleep patterns. Mobility is affected by the disease, and Biogen says collecting data on a daily basis—about how much and how fast MS patients walk, for example—could yield data about the progression of the disease and lead to better treatments.
“Let’s say you see a patient four times a year—that’s two hours per year,” says Al Sandrock, Biogen’s chief medical officer. “You’re losing 364.9 days of other data that could be collected.”
The data also could help Biogen prove the value of its pricey medications to health insurers and pharmacy benefit managers, who are responding to rising drug prices by reducing the number of medicines covered. “It’s a smart investment,” says Tim Coetzee, chief research officer of the National MS Society. Express Scripts dropped Bayer’s MS drug Betaseron, directing patients to three other options, including Biogen’s Avonex. MS drugs cost at least $50,000 a year at wholesale prices, Coetzee says. “Having the tools to demonstrate the value of a particular agent is valuable,” he says.

“Betaseron is comparably priced to other MS treatments,” says Rosemarie Yancosek, a Bayer spokeswoman.
Decisions about which drugs to cover depend on several factors, says Express Scripts spokesman Brian Henry, including the number of drugs on the market, how they work, and their price. None of Biogen’s five MS drugs—Avonex, Fampyra, Plegridy, Tysabri, and Tecfidera—has been taken off the pharmacy benefit managers’ lists. The medicines are projected to bring in almost $8 billion in revenue this year.
 Keep CURRENT with MS Views and News - OPT-IN here


No comments: